News
BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute
BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy candidates. Analysts say the M&A deal is a way to essentially settle out of court the ongoing mRNA patent dispute between the companies following some recent CureVac legal wins.
BioNTech has announced that it will be expanding its messenger RNA (mRNA) capabilities by acquiring CureVac for approximately ...
BioNTech hat vereinbart, den ehemaligen Corona-Impfstoffkonkurrenten CureVac für rund 1,25 Milliarden Dollar (1,08 Milliarden ...
The major averages were mixed near noon with the Dow the laggard as a pullback in Boeing weighs on the Industrials index. U.S ...
The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
The Trump administration had said it would disclose by Wednesday the target prices for drugs, but pharma companies are still ...
Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback